← All trials
NCT04307953
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 13, 2020
- Primary completion
- Aug 1, 2022
- Completion date
- Aug 1, 2022
- First posted
- Mar 13, 2020
- Last posted
- Mar 17, 2020
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Free University of AmsterdamLead sponsor
- Free University of AmsterdamReponsible party - principal investigator
- Harvard UniversityCollaborator
- AstraZenecaCollaborator
- University of OxfordCollaborator
- Royal National Orthopaedic Hospital NHS TrustCollaborator
- European CommissionCollaborator
- University of AmsterdamOverall official - principal investigator
- Klinikum Garmisch-PatenkirchenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.